IL-17 inhibitors block interleukin-17, the cytokine that drives the thickened, scaly plaques of psoriasis and the joint inflammation of psoriatic arthritis and axial spondyloarthritis. They work fast — many patients see clear skin within weeks. Most target IL-17A itself; one blocks IL-17A and IL-17F together, and one blocks the receptor they both bind to.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons